Literature DB >> 19509145

Toward an effective targeted chemotherapy for multiple myeloma.

Andrew G Polson1, Mark X Sliwkowski.   

Abstract

Antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells. Anti-CD138 ADCs show promising preclinical efficacy for the treatment of multiple myeloma; however, the safety aspects of targeting CD138 have yet to be explored.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19509145     DOI： 10.1158/1078-0432.CCR-09-0572

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  4 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 2.  Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.

Authors:  Falk Hiepe; Thomas Dörner; Anja E Hauser; Bimba F Hoyer; Henrik Mei; Andreas Radbruch
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

Review 3.  Development of target-specific treatments in multiple myeloma.

Authors:  Asher A Chanan-Khan; Ivan Borrello; Kelvin P Lee; Donna E Reece
Journal:  Br J Haematol       Date:  2010-07-07       Impact factor: 6.998

Review 4.  The Application of CAR-T Cells in Haematological Malignancies.

Authors:  Katarzyna Skorka; Katarzyna Ostapinska; Aneta Malesa; Krzysztof Giannopoulos
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2020-11-06       Impact factor: 4.291
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.